The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile☆,☆☆,★
Section snippets
Human sera
Sera were obtained from 44 patients with clinically, histologically, and immunopathologically typical PV and 23 patients with typical PF. Patients with PV were classified as having mucosal dominant type and mucocutaneous type. Mucosal dominant type showed predominant oral erosions with limited skin involvement, which was no more than 5 or 6 scattered or isolated erosions or blisters no larger than 5 cm in diameter. Mucocutaneous type showed extensive skin involvement in addition to oral
Mucosal dominant PV has only anti-Dsg3 IgG, but mucocutaneous PV has both anti-Dsg3 and anti-Dsg1 IgG
When we examined the clinical phenotype of PV, this disease could be further divided into two subgroups. One is a mucosal dominant type, which has extensive oral erosions or nasal, esophageal, or ocular erosions with limited involvement of the skin. This phenotype can have several scattered skin blisters or erosions. The other is a mucocutaneous type that has extensive skin blisters and erosions in addition to oral and other mucosal involvement. In general, the mucocutaneous type tends to be
DISCUSSION
It has been documented that some patients with PV have only anti-Dsg3 antibody, whereas other patients with PV have both anti-Dsg1 and anti-Dsg3 antibody.5, 6, 7 However, it was unclear whether there is any difference in the clinical phenotype of Dsg1(-) PV and Dsg1(+) PV patients. Previously we noted that patients with PV who have significant skin involvement tend to have higher anti-Dsg1 IgG titers than those with predominant oral lesions.11 Our previous study included some serum samples
Acknowledgements
We are grateful to Dr John R. Stanley for insightful discussions. We thank Mrs Minae Suzuki for help with the ELISA work and Dr Kazuhiko Ohya for preparing the reagents for Dsg3 and Dsg1 ELISA.
References (13)
- et al.
Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion
Cell
(1991) Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion
Adv Immunol
(1993)- et al.
Identification of the ubiquitous human desmoglein, Dsg2, and the expression catalogue of the desmoglein subfamily of desmosomal cadherins
Exp Cell Res
(1994) - et al.
Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1
J Invest Dermatol
(1995) - et al.
Pemphigus sera recognize conformationally sensitive epitopes in the amino-terminal region of desmoglein-1 (Dsg1)
J Invest Dermatol
(1995) - et al.
Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus
J Invest Dermatol
(1995)
Cited by (377)
Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus
2021, Journal of Investigative DermatologyCitation Excerpt :Pemphigus (vulgaris and foliaceus) is a debilitating disease with painful blisters of the skin and mucosal surfaces that can cause severe and fatal complications. The disease is characterized by IgG autoantibodies directed at the desmosomal cadherins desmogleins (DSGs) 1 and 3, important for keratinocyte cell adhesion in tissues subjected to mechanical stress (Amagai et al., 1999; Huijbers et al., 2018). Disease activity is associated with the levels of anti-DSG1 and anti-DSG3 autoantibodies in the circulation, and their reduction has been shown to correlate with clinical response (Joly et al., 2017; Yeoh et al., 2019).
Homozygous deletion of the DSG3 terminal exon associated with acantholytic blistering of the oral and laryngeal mucosa
2024, American Journal of Medical Genetics, Part ACould ELISA methods be used instead of indirect immunofluorescence in the diagnosis of autoimmune bullous dermatoses?
2023, Rivista Italiana della Medicina di LaboratorioPemphigus and pemphigoids: Clinical presentation, diagnosis and therapy
2023, JDDG - Journal of the German Society of DermatologyT cell autoimmunity and immune regulation to desmoglein 3, a pemphigus autoantigen
2023, Journal of Dermatology
- ☆
Supported by Grant-In-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan, and Research Grants for Life Sciences and Medicine, Keio University Medical Science Fund, and Keio Gijuku Academic Development Funds.
- ☆☆
Reprint requests: Masayuki Amagai, MD, PhD, Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
- ★
0190-9622/99/$8.00 + 0 16/1/95202